Emerging Nontraditional Therapies in Diabetic Kidney Disease: Evidence from 12 Clinical Trials

Introduction

Diabetic Kidney Diseases (DKD) remain a leading cause of Chronic Kidney Disease (CKD) and End Stage Renal Failure (ESRD) worldwide. Conventional therapies confer only partial protection from disease progression. Recent clinical trials have explored novel therapeutic agents that target non-traditional pathways and offer potential reduction in Renal and Cardiovascular morbidity in patients with Type II Diabetes.

Methods

A data-driven review was conducted by extracting efficacy and safety outcomes from Phase II and III clinical trials published between 2019–2025, focusing on three emerging therapeutic classes: the nonsteroidal mineralocorticoid receptor antagonist finerenone, the dual SGLT1/2 inhibitor sotagliflozin, and the endothelin A receptor antagonist atrasentan. Key renal outcomes included reductions in albuminuria and slowing of estimated glomerular filtration rate (eGFR) decline, while cardiovascular outcomes and adverse events were also evaluated.

Results

Across 12 Phase II and III trials encompassing over 19,000 patients with DKD, unconventional therapies demonstrated consistent renal and cardiovascular benefits. Finerenone (n≈5,700) reduced the risk of kidney failure or cardiovascular death by 18% (HR 0.82; 95% CI 0.73–0.93; P=0.001) and the composite kidney outcome by 23–32%, while slowing eGFR decline by up to 20%. Sotagliflozin (n≈10,500) reduced kidney disease-related events by 20–24%, improved albuminuria, and decreased cardiovascular events, including heart failure hospitalizations, with pooled analyses showing a 24% reduction in composite cardiovascular endpoints (HR 0.76; 95% CI 0.70–0.83; P<0.001). Atrasentan (n≈2,900) lowered proteinuria by 30–36% (95% CI −44.6 to −26.4; P<0.001) and reduced the risk of kidney failure or doubling of serum creatinine by 35% (HR 0.65; 95% CI 0.49–0.88; P=0.005). Fluid retention remained the primary adverse effect. Collectively, these agents demonstrated statistically significant improvements in renal and cardiovascular outcomes across diverse DKD populations, offering clear advantages over standard therapy.

Conclusions

Emerging therapies such as finerenone, sotagliflozin, and atrasentan show substantial promise in mitigating renal and cardiovascular complications in DKD. Their unique mechanisms highlight a new paradigm in disease management, offering potential benefits beyond standard glycemic and blood pressure control.